Scientists at ETH Zurich have built a molecular switch that uses light to wake dormant lung cancer cells from hiding — and the results in lab tests are turning heads across the oncology world.
Story Snapshot
- ETH Zurich researchers created light-controlled molecules called photoPROTACs that can pull sleeping lung cancer cells out of their dormant, treatment-resistant state.
- The switch works in both directions — one wavelength of light turns the molecule on, another turns it off — giving doctors a potential way to target only tumor tissue.
- Lab tests on human non-small-cell lung cancer cells confirmed the dormancy was reversed, with genetic analysis backing up the result.
- The study has only been done in cell cultures so far, and a major barrier remains: the light wavelengths used do not travel deep into living tissue.
Why Sleeping Cancer Cells Are Such a Dangerous Problem
Cancer cells are not always actively growing. Some go quiet, entering a dormant state where they stop dividing and become nearly invisible to the immune system and most treatments. They can stay hidden for years, even decades. Then, without warning, they wake up and spread. This is one of the main reasons cancer comes back after a patient seems cured. Solving the dormancy problem has been one of oncology’s hardest puzzles.
A key driver of this dormancy in lung cancer is the glucocorticoid receptor, a protein that responds to stress hormones. When this receptor is active, it can push cancer cells into that hidden, sleeping state. ETH Zurich’s team set out to destroy that receptor — but only inside the tumor, not in healthy tissue nearby.
How the Light Switch Actually Works
The researchers built their tool by combining two existing technologies. Proteolysis Targeting Chimeras, known as PROTACs, are molecules already known for tagging specific proteins for destruction inside cells. The ETH Zurich team added a photoswitchable element to make them light-responsive, creating what they call photoPROTACs. The result is a molecule that destroys the glucocorticoid receptor only when activated — and light controls that activation.
The design has a clever twist. The molecule is active in the dark and switches off when hit with ultraviolet light. The plan is to inject it into a tumor, then shine light on the surrounding healthy tissue to turn off any molecules that drift away from the target. Activity stays locked inside the tumor core. “Activity can therefore be strictly limited to the tumour core, preserving the surrounding tissue and causing significantly fewer side effects,” said Robin Scheuplein, joint first author of the study.
What the Lab Tests Showed
In cell cultures of human non-small-cell lung cancer, the active form of the molecule caused rapid breakdown of the glucocorticoid receptor. Genetic analysis across thousands of genes confirmed that the dormant cells shifted back toward an active state. The inactive form of the molecule, used as a control, left those genes essentially untouched. That clean separation between active and inactive forms is exactly what a precision therapy needs to show before moving forward.
The researchers published their findings in the Proceedings of the National Academy of Sciences in May 2026. The system is also modular, meaning it could in principle be adapted to target other receptors involved in breast and prostate cancer, not just lung cancer.
The Real Hurdle Still Standing Between Lab and Patient
Here is where honest science requires a cold splash of water. The study was done entirely in cell cultures. No animals. No humans. The ultraviolet and visible light needed to flip the switch does not travel far through living tissue — a well-known barrier in light-based cancer treatment. The researchers themselves acknowledge that future versions will need to respond to red or near-infrared light, which penetrates tissue much more deeply, before this can move toward clinical use.
Some media coverage leaned hard into “cancer kill switch” language, which overstates where this technology actually stands. That kind of framing does patients a disservice. The science here is genuinely exciting — but it is early-stage science. The path from a promising cell-culture result to an approved therapy is long, expensive, and full of failures. The next step the team has planned is testing in organoid models, which are more complex than flat cell cultures but still far from a living patient. Keeping expectations grounded is not pessimism. It is respect for how hard this problem really is.
Sources:
sciencedaily.com, instagram.com, news-medical.net, ethz.ch, x.com
